Gut microbial metabolites in obesity, NAFLD and T2DM.

Nat Rev Endocrinol 2019 05;15(5):261-273

Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, Netherlands.

Evidence is accumulating that the gut microbiome is involved in the aetiology of obesity and obesity-related complications such as nonalcoholic fatty liver disease (NAFLD), insulin resistance and type 2 diabetes mellitus (T2DM). The gut microbiota is able to ferment indigestible carbohydrates (for example, dietary fibre), thereby yielding important metabolites such as short-chain fatty acids and succinate. Numerous animal studies and a handful of human studies suggest a beneficial role of these metabolites in the prevention and treatment of obesity and its comorbidities. Interestingly, the more distal colonic microbiota primarily ferments peptides and proteins, as availability of fermentable fibre, the major energy source for the microbiota, is limited here. This proteolytic fermentation yields mainly harmful products such as ammonia, phenols and branched-chain fatty acids, which might be detrimental for host gut and metabolic health. Therefore, a switch from proteolytic to saccharolytic fermentation could be of major interest for the prevention and/or treatment of metabolic diseases. This Review focuses on the role of products derived from microbial carbohydrate and protein fermentation in relation to obesity and obesity-associated insulin resistance, T2DM and NAFLD, and discusses the mechanisms involved.

Download full-text PDF

Source
http://www.nature.com/articles/s41574-019-0156-z
Publisher Site
http://dx.doi.org/10.1038/s41574-019-0156-zDOI Listing
May 2019
72 Reads

Publication Analysis

Top Keywords

insulin resistance
8
fatty acids
8
major energy
4
energy source
4
source microbiota
4
fibre major
4
fermentable fibre
4
availability fermentable
4
microbiota limited
4
proteins availability
4
proteolytic fermentation
4
products ammonia
4
ammonia phenols
4
harmful products
4
yields harmful
4
peptides proteins
4
fermentation yields
4
limited proteolytic
4
microbiota ferments
4
studies beneficial
4

References

(Supplied by CrossRef)

ZM Younossi et al.
Hepatology 2016

Y Zheng et al.
Nat. Rev. Endocrinol. 2017

T Seuring et al.
Pharmacoeconomics 2015

M Tremmel et al.
Int. J. Environ. Res. Public Health 2017

E Corpeleijn et al.
Obes. Rev. 2009

GI Shulman et al.
N. Engl. J. Med. 2014

SM Reilly et al.
Nat. Rev. Endocrinol. 2017

R Stinkens et al.
Obes. Rev. 2015

F Bäckhed et al.
Proc. Natl Acad. Sci. USA 2004

RE Ley et al.
Nature 2006

Similar Publications